M. Gharaibeh

发表

Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer

D. Alberts, B. Erstad, M. Slack, 2018, PharmacoEconomics.

Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritis

C. Cameron, A. Varu, A. Lau, 2019, BMC Medical Research Methodology.

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients

K. Denhaerynck, I. Abraham, K. MacDonald, 2017, International journal of chronic diseases.

Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States.

B. Erstad, J. Karnes, I. Abraham, 2016, Blood.

Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer

I. Abraham, A. McBride, J. Bootman, 2017, Journal of medical economics.

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

M. Piccart, L. Carey, A. Bardia, 2022, European journal of cancer.

Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting

J. Greenberg, P. Mease, D. Collier, 2019, Rheumatology International.

Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer

D. Alberts, B. Erstad, M. Slack, 2018, PharmacoEconomics.

Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review

I. Abraham, Jennifer R Martin, A. McBride, 2016, PharmacoEconomics.

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer

I. Abraham, A. McBride, J. Bootman, 2015, British Journal of Cancer.

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data

M. Bonafede, B. Stolshek, M. Gharaibeh, 2020, Journal of managed care & specialty pharmacy.

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate

D. Collier, J. Tkacz, M. Gharaibeh, 2020, Journal of managed care & specialty pharmacy.

Influence of Health and Functional Status and Co‐occurring Chronic Conditions on Healthcare Expenditures Among Community‐dwelling Adults With Kidney Cancer in the United States: A Propensity–score‐matched Analysis

I. Riaz, S. Bhattacharjee, M. Kamal, 2017, Clinical genitourinary cancer.

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure

B. Erstad, J. Karnes, M. Slack, 2020, American Journal of Cardiovascular Drugs.

Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure

B. Erstad, J. Karnes, M. Slack, 2018, Expert Review of Precision Medicine and Drug Development.

Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators

V. Strand, J. Jansen, D. Incerti, 2017, Journal of medical economics.

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry

P. Mease, D. Collier, M. Gharaibeh, 2021, Arthritis Research & Therapy.

Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P+GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC).

I. Abraham, L. Cranmer, A. McBride, 2015 .